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Abstract
Background: Aim of our study is to investigate the clinical and immunological outcomes according to first-line
HAART adherence in a large cohort of HIV-infected patients in Burkina Faso.
Methods: A retrospective study was conducted between 2001 and 2009 among patients from two urban medical
centers [St. Camille Medical Center (CMSC) and “Pietro Annigoni” Biomolecular Research Center (CERBA)] and 1 in
the rural District of Nanoro (St. Camille District Hospital). Socio-demographical and clinical data were analyzed.
Adherence was evaluated through a questionnaire investigating 5 key points related to drugs, consultations and
blood exams, by assigning 0 to 2 points each up to 10 points overall. Data were collected at baseline and regularly
thereafter. Adherence score was considered as a continuous variable and classified in optimal (8–10 points) and
sub-optimal (0–7 points). Immunological outcome was evaluated as modification in CD4+ T-cell count over time,
while predictors of death were explored by a univariate and multivariate Cox model considering adherence score
as a time-varying covariate.
Results: A total of 625 patients were included: 455 (72.8%) were females, the median age was 33.3 (IQR 10.2) years,
204 (32.6.%) were illiterates, the median CD4+ T-cell count was 149 (IQR 114) cells/μl at baseline. At the end of the
observation period we recorded 60/625 deaths and 40 lost to follow-up. The analysis of immunological outcomes
showed a significant variation in CD4+ T-cell count between M12 and M24 only for patients with optimal adherence
(Δ=78.2, p<0.001), with a significant Δ between the two adherence groups at M24 (8–10 vs 0–7, Δ=53.8, p=0.004).
Survival multivariate analysis revealed that covariates significantly related to death included being followed at CERBA
(urban area) or Nanoro (rural area), and receiving a regimen not including fixed dose combinations, (p=0.024, p=0.001
and p<0.001 respectively); conversely, an increasing adherence score as well as an optimal adherence score were
significantly related to survival (p<0.001).
Conclusions: Adherence to HAART remains pivotal to build up a good therapeutic outcome. Our results confirm that,
according to our adherence system evaluation, less adherent patients have a higher risk of death and of inadequate
CD4+ count recovery.
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Background
It is estimated that about 32.2 million people were living
with HIV at the end of 2012. Two thirds of HIV infections
(approximately 23.5 million people) were in Sub-Saharan
Africa, where a high prevalence of HIV/AIDS is reported
(4.7%) [1]. The introduction of Highly Active Antiretro-
viral Therapy (HAART) in 1996 has considerably changed
the clinical outcomes of infected patients, leading to a dra-
matic improvement in quality of life and decline in AIDS-
related deaths in low-income Countries [2,3]. By the end
of 2012, the number of people receiving antiretroviral
therapy reached 9 million, meaning a 20-fold increase in
treatment coverage compared to 2003 [1].
In many low-income Countries, where sometimes
neither viral nor immunological parameters are available,
adherence monitoring may be an acceptable instrument
to estimate HAART effectiveness [4,5]. Besides, second-
line regimens are still not easily available in these areas,
thus making adherence to a first-line treatment even more
important since its failure could leave the patients with no
other therapeutic choices. Therefore, some studies have
been carried on to better assess adherence patterns in
Low and middle-income Countries [6,7] or to correlate
adherence with patients outcome [8-11].
WHO usually defines adherence to any treatment as
“the extent to which a person’s behavior-taking medica-
tion, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from a health-
care provider”. Since no measurement strategy can be
considered optimal especially when used alone, an holistic
approach is currently suggested [12].
Actually, adherence assessment remains a rather chal-
lenging task: direct observation therapy is not practical
for HAART regimens that have to be taken lifelong.
Methods to establish adherence to antiretroviral treat-
ment include pill count, pharmacy refill records, various
self-reporting tools such as questionnaires and visual
analogue scales, detection of drug blood levels and
electronic monitoring devices [13]. The most com-
monly applied techniques in low-income Countries
are pills count and self reports, though they often overesti-
mate adherence [14].
On the other hand, it was demonstrated that the avail-
ability of various types of adherence support may avoid
attrition to antiretroviral therapy [15].
Previously conducted studies concerning adherence to
antiretrovirals found that a 95% minimum rate of drug
assumption is required in order to guarantee a viro-
immunological effectiveness of the therapy [16]. Also in
Burkina Faso, the moderate spread of HIV drug resist-
ance strains (from 5 to 15%) for both nucleoside reverse
transcriptase inhibitors (NRTIs) and a non-nucleoside
reverse transcriptase inhibitor (NNRTI) among HIV-
infected women attending antenatal care, indicates that
patients receiving antiretroviral therapy should be ade-
quately supported in order to improve adherence and to
avoid a further diffusion of resistance mutations [17].
Aims of this study are to explore death and CD4+ T-cell
count evolution according to an original adherence score
and to investigate predictors of death in a large co-
hort of HIV-infected patients over the first 24 months
of treatment.
The study presented here was conducted within the
European ESTHER (Ensemble pour une Solidarité
Thèrapeutique Hopitalière en Reseau) project, a 9-year
collaborative experience devoted to give assistance as well
as technical and scientific support to fight HIV/AIDS in a
low-income Countries.
Methods
Study design and population
This is a longitudinal observational single-cohort retro-
spective study that involved 3 different health facil-
ities in Burkina Faso, 2 located in the suburban area of
Ouagadougou [St. Camille Medical Center (CMSC) and
“Pietro Annigoni” Biomolecular Research Center (CERBA)]
and 1 in the rural District of Nanoro (St. Camille District
Hospital). We enrolled all HIV-infected adults who started
HAART according to WHO international guidelines avail-
able in the study period [18,19], between January 2001
and February 2009. Patients were followed since HAART
beginning for at least one year afterwards, two years when
feasible.
All data were collected in Burkina Faso (a West-African
country with a population of about 13.2 million people)
which is among the poorest countries in the world (181st
position out of 187) [20]. Notably, in this country only
49% of the 64000 estimated HAART-needing patients
were actually receiving it by the end of 2010 [17].
Data collection
Consultations and data collection were performed by a
medical doctor, available for both scheduled and emer-
gency visits. Routine clinical visits where conducted accor-
ding to WHO international guidelines [18,19]. Patients
enrolled in the study, were evaluated at baseline (D0), on
day 15 (D15), each month during the first semester
(M1-M6) and thereafter every three months since HAART
initiation. Each time, WHO clinical stage and adherence
score (from D15 on) were registered. Furthermore, CD4+ T
cell count was scheduled on D0 and then at M6, M12 and
M24, together with some routine laboratory tests (i.e. blood
cell count, transaminases, creatinine, amylasemia and gly-
caemia). During the study, patients were categorized into
(i) followed, (ii) lost to follow-up, (iii) dead and (iv) referred
to other Medical Centers. A patient was considered lost to
follow up if he/she had missed 2 consecutive visits without
a further contact. Demographical and clinical variables,
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social behaviors, family conditions and literacy were also
analyzed.
Adherence score
Adherence was assessed through the administration of a
questionnaire regarding 5 different aspects: (1) pills
count, (2) delays and omissions in taking pills referred
from patient, (3) knowledge of posology, (4) punctuality
on consultations, (5) proper execution of blood tests as
planned at the previous consultation. A score was esti-
mated by the medical doctor who performed the visit
through the assignment of 0 (i.e. unreached goal), 1 (i.e.
partially reached goal) or 2 (i.e. fully reached goal) points
to each feature, up to 10 points overall. This score has
not been validated. Treatment interruption was deter-
mined as a referred and/or planned history of stopping
and resuming treatment, and corresponds to a zero
score. On the other hand, a full adherence score was
attributed to patients (1) who took at least 95% of pills
(as stated through direct count and self report of missed
doses), (2) at the right time of the day (with 30 minutes
tolerance), (3) who properly knew the regimen posology,
(4) presented on scheduled consultations (± 2 days, since
extra-medications were provided) and (5) underwent
blood tests as planned. If a patient was lost to follow up
(see above), no value was assigned to the adherence
score, and the patient was considered in the statistical
analysis only according to the period of follow-up.
Statistical analysis
Associations between categorical variables were evalu-
ated using Chi-square tests or Fisher exact tests where
needed. Overall survival was modeled using Cox models
considering adherence score as time-varying covariate.
The following variables were considered in univariate
analyses: center, age (continuous), gender, religion, living
area, HIV type infection, literacy, CD4+ T-cell count,
WHO clinical stage, HAART regimen including fixed
dose combination (FDC), calendar year and adherence
score (as continuous and categorical [0–7,8–10] variable)
and those significant were included in a multivariate Cox
model. Model selection for the multivariate Cox model
was based on likelihood ratio tests. The final model in-
cluded center, HAART regimen including FDC, calendar
year, WHO clinical stage and adherence score (as continu-
ous and categorical [0–7,8–10] variable). Both calendar
year and WHO clinical stage were included as a stratifi-
cation variable. When performing the survival analysis, all
patients lost to follow-up were censored.
CD4+ T-cell count variation over time was modeled
using a random-intercept linear mixed model [21] with
CD4+ T-cell expressed on the squared root scale. Model
selection was performed based on likelihood ratio tests
both for fixed and random effects of the model. Within-
subjects errors were auto-correlation was modeled using
a continuous first-order autoregressive process (CAR1)
with an estimated autocorrelation coefficient of 0.66.
The final model included sex, age (continuous), center,
WHO HIV clinical stage, HAART regimen including
FDC, baseline CD4+ T-cell count, adherence score (cate-
gorized as [0–7,8–10]), HIV type infection (HIV-1, HIV-
2 or HIV 1 and 2 mixed) as well as HAART regimen
including FDC-time and score-time interaction terms.
Considering the possibility of a missing not at random
pattern and its potential effects on model estimates we
conducted a sensitivity analysis fitting a linear mixed
model as specified above only on subjects that had a visit
at 24 months. Results did not differ from the model with
all data (data not shown).
All analysis were performed using the R statistical soft-
ware [22] and specifically the packages survival [23] and
nlme [24]. All statistical tests were performed based on a
significance level of 5%.
Ethics
The Study was conducted in compliance with the Helsinki
declaration. The Joint Centre Médicale Saint Camille and
Centre de Recherche Biomoléculaire Pietro Annigoni Ethics
Committee were duly informed about the ongoing research
and gave their permission. In fact, the CNERS (Comité
National d’éthique pour la Recherche en Santé) is ques-
tioned only in case of interventional clinical trials as well as
in international or national pharmacological studies: there-
fore in this case it was not informed. Moreover, being a
retrospective non-interventional study founded on post hoc
analysis of data already present in patients’ files, and col-
lected only for clinical indications, no written informed
consent was asked to patients.
Results
Patients characteristics
A total of 625 HIV-infected patients who started
HAART between January 2001 and February 2009, were
included. Socio-demographic and clinical features of this
cohort are showed in Tables 1 and 2 respectively. Pa-
tients were followed for a median time of 20.8 months
(min. 0.6 – max 24 months). Most individuals were fe-
male (455/625, 72.8%) and the median age at enrollment
was 33.3 (IQR 10.2) years. Moreover, a large proportion
of patients had a stable partner (59.3%), many were
widowed (23.0%) and 17.1% had no stable partner. With
respect to literacy, 32.6% (204/625) of patients were
illiterate. Notably, only 57.8% of enrolled subjects
spoke French, nearly all the others knew local dialects
only. The 74.6% (466/625) of patients were living in
Ouagadougou, while the remaining 25.4% (159/625)
were from rural areas.
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At the beginning of antiretroviral treatment, a signifi-
cant proportion of patients belonged to an advanced WHO
clinical stage (50.6%, 316/625) and the median CD4+ abso-
lute count was 149 cells/μl (IQR 114). Overall, 63/625
patients (10.1%) had a concurrent HBV or HCV chronic
infection. The 87.8% (549/625) of prescribed HAART reg-
imens consisted of two nucleoside reverse transcriptase
inhibitors (NRTIs) and a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), while the remaining 12.2%
(76/625) were made up of two NRTIs and a protease
inhibitor (PI). Moreover, 75.8% (474/625) of patients
received FDC (e.g. Zidovudine/Lamivudine, Stavudine/
Lamivudine/Nevirapine, Stavudine/Lamivudine).
By the end of follow-up, 9.6% of patients (60/625) had
died, 5.9% (37/625) had been referred, 6.4% (40/625)
Table 1 Socio-demographic characteristics of patients at
baseline




Median age at baseline







-Only local dialects 237/625 (37.9)







Calendar year of enrolment
in the whole cohort







-Stable partner 371/625 (59.3)
-No stable partner 107/625 (17.1)
-Widowed 144/625 (23.0)








-Missing data 127/408 (31.1)
Table 1 Socio-demographic characteristics of patients at
baseline (Continued)
Status at the end of follow-up
-Followed 488/625 (78.1)
-Lost to follow-up 40/625 (6.4)
-Dead 60/625 (9.6)
-Referred 37/625 (5.9)
Notes: IQR: Interquartile range. All values are expressed as N (%).
Table 2 Clinical characteristics of patients at baseline
Variable All patients (N = 625)
Median CD4+ T cell count at
baseline (cells/μl)
cells/μl [median (IQR)] 149 (114)
[calculated on 593/625 pts]
CD4 T cell count at baseline
-< 50 cells/μl 88/593 (14.8)




-HIV-1 + HIV-2 28/625 (4.5)
WHO clinical stage at baseline
-Early (stage 1 and 2) 309/625 (49.4)
-Advanced (3 and 4) 316/625 (50.6)
HAART regimen
-2NRTIs + 1NNRTI 549/625 (87.8)
-2NRTIs + 1PI/r 76/625 (12.2)
HAART regimen including FDC
-Yes 474/625 (75.8)
-No 151/625 (24.2)
Notes: IQR: Interquartile range; HAART: highly active antiretroviral therapy;
NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non nucleoside
reverse transcriptase inhibitors; PI/r: protease inhibitors boostered by ritonavir;
FDC: fixed dose combination; All values are expressed as N (%).
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were lost to follow-up and 78.1% (487/625) were still
under active monitoring. Median follow-up for subject
censored before the end of the study (24 months) was
8.97 months, in particular median follow-up for dead pa-
tients was 6.54 months.
CD4+ T cell count increase according to adherence score
To evaluate the immunological outcome, we consid-
ered two different groups of patients based on adher-
ence score considered at each time-point. We divided
patients with optimal adherence (8–10 points) from
those with sub-optimal adherence (0–7 points). We
observed a significant increase in CD4+ T-cell count
from baseline to M6, both in the 0–7 (Δ = 112.4, p <
0.001) and 8–10 groups (Δ = 120.7, p < 0.001), while
the difference between the two groups at M6 was not
significant (p = 0.56). Moreover, from M6 to M12 we
found a CD4+ T-cell count significant variation in both
adherence groups (Δ = 62.6 p < 0.001 and Δ = 38.1 p <
0.001 in the 0–7 and 8–10 group respectively), and a
non-significant difference was observed between the
two groups at M12 (p = 0.39). A significant variation
was observed between M12 and M24 only in the 8–10
group (Δ = 78.2, p < 0.001) with a significant Δ between
the two groups at M24 (8–10 vs 0–7, Δ = 53.8, p = 0.004).
Figure 1 shows the estimated Δ (from G0) and their stand-
ard errors.
Survival and predictors
Univariate and multivariate logistic regression analysis
were conducted to explore the possible predictors of
death as summarized in Table 3. In univariate analysis
factor independently associated with death were: be-
ing followed at CERBA or Nanoro (p <0.001 for both
variables), living in rural area, increasing age, early
HIV disease clinical stage and receiving a HAART
regimen not including FDCs (p = 0.008, p = 0.076, p =
0.013 and p < 0.001 respectively). Besides, factors inversely
related to death were increasing adherence score (for 1-
point increase) and optimal adherence score (8–10 point),
both considered as time-varying covariates (p < 0.001 and
p < 0.001 respectively). In the multivariate model covari-
ates significantly associated with death included being
followed at CERBA or Nanoro and receiving a regimen
not including FDCs, (p = 0.024, p = 0.001 and p < 0.001
respectively); the increasing adherence score and the opti-
mal adherence score (8–10 points) were confirmed to be
significantly related to survival (p < 0.001 for both).
Discussion
In this study we observed a direct correlation between
the two different outcomes (survival and CD4+ T-cell
count recovery) and adherence evaluated through our
score: our data substantially confirm previous findings
[25,26] suggesting that good adherence enhances CD4+
T-cell recovery and decreases mortality.
A significant proportion of our study population was
represented by women (72.8%), since CMSC is a medical
center devoted to “mother and child health-care” where
patients are predominantly pregnant women and their
HIV-infected partners [27]. Hence, patients who went to
CMSC were usually asymptomatic at enrolment (i.e. at
an early WHO clinical stage at baseline). Conversely, the
other two centers mainly admit symptomatic individuals
and hospitalized late presenters.
Moreover, people coming from Nanoro rural District
often emigrate particularly to Ivory Coast, delaying access
to HIV screening and care [28]. The high proportion of
HIV-infected migrants on HAART who work abroad may
be partly responsible for the worsening of therapeutic ad-
herence in this setting. This phenomenon was taken into
account during the statistical analysis and the multivariate
logistic regression model was realized after stratifying for
WHO clinical stage at baseline and for calendar year.
The lack of a gold standard method to evaluate adher-
ence brought us to use a multi-parametric strategy based
on a combination of questionnaires, pills count, punctu-
ality on clinical consultations and blood tests. This
method allowed us to bypass single measurements–re-
lated biases, by taking into account several aspects of
treatment adherence according to WHO recommenda-
tions [12]. Previous studies employed a variety of
methods to assess adherence, with different thresholds
to define good adherence, and a wide range of adherent
patients proportions were reported (from 20.7 to 93.5%)
[10,11,29-34]. Since the methodologies of these studies
widely varied from each other, they are not easily com-
parable to our research.
Figure 1 Estimated mean Δ CD4+ T cell count evolution. The
plot represents estimated mean Δ CD + T counts separately for
optimal (8–10) and suboptimal (0–7) adherence levels at every visit
(6 months, 12 months and 24 months). Bars represent the standard
error of the means.
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The increase in CD4+ T-cell count was similar in pa-
tients with optimal and suboptimal adherence (0–7 and
8–10 group) during the first year of follow-up, while a bet-
ter adherence (8–10 group) during the second year was
significantly related to a progressive increase in CD4+ T-
cell count. Our findings are in line with those described in
the DART trial where investigators observed a worse im-
munological recovery (assessed through the CD4+ T-cell
count evolution) among less-adherent patients.
We also found that good adherence is strongly related
to a lower risk of death in univariate and multivariate
models, given that the adherence score was considered
as continuous variable or as a binomial variable (8–10 vs
0–7 points).
The univariate analysis of death predictors revealed that
living in urban areas was associated to a better survival,
while the other socio-demographic features (education, re-
ligion, gender and increasing age) were not. In fact, living
in a urban area is likely to be associated with fewer disrup-
tions in access to medicines, which seem to facilitate ad-
herence [35-37]. Moreover, WHO clinical stage at
baseline resulted to be significantly related to death, while
CD4+ T-cell count (<50 vs >50 cells/μl) did not.
The multivariate analysis showed an increased risk of
death among patients who were followed at CERBA or
Nanoro as compared to those followed at CMSC, as a
consequence of the above-mentioned differences be-
tween patients enrolled in the three healthcare facilities.
In addition, receiving a regimen including FDCs was
confirmed to be significantly related to survival, suggest-
ing the importance of a wider access to HAART in low-
income Countries with a particular attention to compact
regimens [38].
At any rate, some limitations should b e taken into
consideration while interpreting our study. First of all, it
was not possible to collect full data for the whole cohort
since medical records were sometimes incomplete or
because patients had died, had been lost to follow-up or
transferred elsewhere. Second, our adherence score has
not been validated and we are not able to establish the
relative weight of each component of the score. More-
over, we did not compare this score with other methods
to evaluate adherence since validation of this score was
not the aim of this study. Lastly, the assignation of our
score is purely at the discretion of the physician who
performed the visit, and it should not be interpreted as a
objective measure. Although the scores assigned at each
visit were equally weighted, despite the variability in the
length of assessment, the patients were followed in
accordance with current WHO guidelines and all data
were analyzed only retrospectively.
Conclusions
In summary, our findings confirm that optimal adherence
is strongly related to better immunological recovery and
survival, though assessed through a non-validated score.
Table 3 Predictors of death: univariate and multivariate analysis
Univariate analysis Multivariate analysis
Variables HR 95% IC p value HR 95% IC p value
Center CERBA vs CMSC 4.98 2.19 – 11.32 <0.001 2.76 1.15 – 6.65 0.024
Nanoro vs CMSC 8.08 3.35 – 19.49 <0.001 10.60 3.78 – 29.75 0.001
Sex M vs F 1.44 0.83 – 2.51 0.21
Religion Muslim vs Christian 0.90 0.52 – 1.54 0.69
Living area Rural vs Urban. 2.12 1.24 – 3.64 0.008 - - -
HIV type infection 2 vs 1 1.29 0.18 – 9.38 0.80
Mixed vs 1 2.31 0.92 – 5.78 0.075
Literacy Illiterate vs literate 1.29 0.75 – 2.23 0.36
Age 1 year increase 1.32 0.98 – 1.79 0.076
CD4+ T-cell count at baseline ≤50 vs >50 1.53 0.74 – 3.17 0.28
WHO HIV clinical stage$ Early vs advanced 0.5 0.29 – 0.88 0.016 - - -
HAART regimen including FDC No vs Yes 2.70 1.58 – 4.59 < 0.001 0.40 0.22 – 0.70 <0.001
Increasing adherence score For 1 point increasing 0.60 0.47 – 0.76 <0.001 0.87 0.81 – 0.93 <0.001
8–10 vs 0–7 0.37 0.21 – 0.63 <0.001 0.32 0.18 – 0.57 <0.001
Calendar year*$ - - - 0.008 - - -
Notes: HR: hazard ratio; CI: confidence interval; CERBA: “Pietro Annigoni” Biomolecular Research Center; CMSC: Centre Médicale Saint Camille, Ougadougou;
HAART: highly active antiretroviral therapy; FDC: fixed dose combination.
*For Calendar Year only p-value for likelihood-ratio test (model with/without variable) reported.
$Variables included in the model as strata.
§p-values below 0.05 (in boldface) were considered to be significant.
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Our results reinforce the need of additional support such
as reminders and enhanced community education [38]. In
fact, HIV/AIDS – related stigma still represents a major
concern in low-income Countries especially in Sub-
Saharan Africa and it is thought to significantly influence
patients’ compliance. Notably, scaling up antiretroviral
treatment coverage alone is not sufficient: adherence im-
provement remains necessary, with a particular attention
to prescribe FDC-containing regimens in order to achieve
both clinical and immunological outcomes.
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